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ABSTRACT 
 
TITLE: Determination of the prevalence of tuberculosis with drug-resistant strains of 
Mycobacterium tuberculosis in Khartoum, Gazira and camps for displaced people, 
Sudan 
RESEARCHER: Muna Obied Ali 
SUPERVISORS: M.D., Ph.D., Professor Gunnar Bjune; M.D. Per Sandven 
The financial support was provided by (NORAD) Norwegian Agency for 
Development Cooperation 
DESCRIPTION OF THE STUDY 
SETTING: Khartoum, Gazira and camps for displaced people 
OBJECTIVES: To find the extent of anti-tuberculosis drug resistance in Sudan and 
to estimate the association between drug resistance-TB and proportion of new cases 
and previously treated cases. And to identify medical, social and demographic factors 
associated with the development of drug-resistant TB 
DESIGN: Strains isolated from 144 patients with pulmonary tuberculosis were 
studied for susceptibility to anti-tuberculosis drugs by the BACTEC method. 
 Data collection forms were filled, to identify factors associated with drug resistance. 
RESULTS: Twenty-seven strains (50%) were resistant to at least one anti-
tuberculosis drugs. Thirty-one (22%) were multi-drug resistant. With exception of 
only 2 cases, all MDR were found among previously treated cases. The highest rate of 
mono-drug resistance was observed for streptomycin in both groups of patients (new 
and previously treated patients). 22 (23.6%) strains collected from new and 8 (15.6%) 
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of strains collected from previously treated patients were resistant to streptomycin 
respectively. Resistance to ethambutol was only seen in multi-drug resistance strains. 
With the exception of only one strain, all strains resistant to rifampicin were multi-
drug resistant. 
In Khartoum 24 (26.4%) were multi-drug resistant, in Gazira 4 (16%) and in the 
camps for displaced people 3 (10.7%) were multi-drug resistant. 
A history of previous treatment for tuberculosis, being more than 40 years of age, 
having long duration of symptoms, low weight and household contact of a TB patient 
were significantly associated with resistance to at least one anti-tuberculosis drug and 
multi-drug resistance. 
CONCULUSIONS: There is a high prevalence of M. tuberculosis strains resistant to 
streptomycin also in new patients; drug resistance except for streptomycin among 
new cases is a rare phenomenon in Sudan, which indicates a low rate of transmission 
of resistant strains. Drug resistance among previously treated patients is present at an 
alarming level.   
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ABBREVIATIONS 
 
AIDS                               Acquired immune-deficiency syndrome 
BCG                                Bacille Calmette Guerin 
CAT                                Category 
CI                                    Confidence interval 
DOTS                              Directly-Observed Treatment, Short course  
DR                                   Drug resistance 
DST                                 Drug susceptibility tests 
E                                      Ethambutol 
H                                      Isoniazid 
HIV                                  Human immunodeficiency virus 
IUATLD                          International Union Against Tuberculosis and Lung Disease 
LHL                                 Norwegian Lung and Heart Association 
MDR                               Multi-drug resistance 
Mtb                                  Mycobacterium tuberculosis 
NAD                                Nicotinamideadenine dinucleotide 
NIPH                               National Institute of Public Health 
NRL                                 National Reference Laboratory 
NTP                                 National Tuberculosis Programme 
OR                                   Odds ratio 
PAS                                 Para-aminosalicylic acid 
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PHC                                Primary Health Care  
QC                                  Quality control 
R                                     Rifampicin 
RNA                               Ribonucleic acid 
rpob                                B-subunit of the RNA polymerase                                                                          
S                                    Streptomycin 
TAD                               Treatment after default 
TB                                  Tuberculosis 
TBMU                          Tuberculosis management unit 
TH                                 Thioacetazone 
WHO                            World Health Organization 
Z                                   Pyrazinamide 
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INTRODUCTION 
 
Tuberculosis global problem 
 
The revision of the epidemiology of TB in the world shows a decline in the rate of the 
infection since the discovery of anti-tuberculosis drugs up to 1984 when it has been 
noticed that the incidence of TB infection had not only stopped to decline in many 
developed countries but was actually increasing. It was realized that the disease was 
out of control across most of the poorest countries of the world. That is why World 
Health Organization (WHO) declared TB to be a global emergency in 1993 (1). 
 
It is estimated that one-third of the global population (1.7 billion people) is infected 
with M. tuberculosis and that 7 to 8 million new cases of TB occur each year. TB 
kills an estimated 2 to 3 million people each year. 
 
Most of the TB cases and deaths from TB occur in developing countries. Increases in 
TB incidence have been observed in developed countries as well. A combination of 
social, economic, historical and factors including urban homelessness, intravenous 
drugs abuse, alcoholism, poor nutrition, immigration from endemic areas, growing 
neglect of tuberculosis control programmes, and mostly the AIDS epidemics, are 
thought to be responsible for this reversal (2). If TB control will not be further 
strengthened nearly 1 billion people will be newly infected, 200 million people will 
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get sick, and 35 million will die from TB between 2000 and 2020 (3). Around 6% of 
all deaths worldwide are attributed to TB (4, 5). It is expected that TB will remain one 
of the 10 leading causes of mortality and morbidity in the world. 
 
The resurgence of TB has been accompanied by increasing rate of drug resistance. 
The spread of M. tuberculosis with drug-resistant and MDR strains is one of the most 
actual problems in infectious diseases. World community is anxious about the 
possibility of the development of dangerous MDR TB that is resistant to at least R 
and H. 
The MDR TB can cause many deaths. Patients infected with resistant especially 
MDR strains, are less likely to be cured, especially if they are co-infected with human 
immunodefiency virus. 
 
TB epidemiology in Sudan 
 
Introduction: 
 
Sudan is the largest country in Africa covering about one million sq. miles. A federal 
government system was adopted in 1992 where the country was divided into 26 
states, 120 provinces and 674 localities. 
 
TB is one of the major health problems in Sudan and considered as one of the top 
health priorities for the government of Sudan. The estimated annual risk of infection 
is 1.8%, which gives an incidence of 90/100.000 smear positive cases that puts Sudan 
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among the high prevalence countries for TB in the East Mediterranean Region. The 
total number of cases in Sudan is estimated to 45,000 cases. The increased number of 
refugees from neighboring countries and the increased number of internally displaced 
population from war-affected areas add to TB burden in Sudan. 
 
 The NTP was established in 1986. Now the programme is implemented in 73 
provinces in 22 states. 
 
NTP has a central unit under the umbrella of Directorate General of Preventive and 
Social Medicine at the Federal Ministry of Health. There is a coordinator in each state 
and province (that are implementing the programme) including laboratory 
supervisors. For more strengthening of the programme and implementation within the 
primary health care system, NTP and national programme for control of leprosy have 
joined together in August 2001. 
 
            NTP is receiving support (drugs, reagents, supplies, logistics) mainly from 
government of Sudan, LHL and WHO.  Since the adoption of directly observed 
treatment strategy, centers are established to cover 75% of the population (493 DOTS 
centers of which 235 are TBMU/DOTS centers). The targets of the programme  are to 
achieve DOTS all over by the end of 2005, a cases detection rate of at least 70% and 
a cure rate of at least 85%.  
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             NTP and National Health Laboratory (NHL) established jointly a National Reference 
Laboratory in 2000. Renovation of the NRL is taking place now. 
 
A senior clinical microbiologist, three junior microbiologists and five technologists 
constitute the staff of the NRL. The staff has received training in national and 
regional courses on culture and susceptibility testing, QC for microscopy centers and 
training of microscopists.  
 
Regarding the national microscopy network for TB, 237 laboratories are established 
(out of national target to establish 280 in order to have one laboratory for each 
100.000 population). There is a laboratory coordinator in each of the 22 states who is 
responsible for supervision and training of state microscopy centers. 
Regarding studies on DR in Sudan there is no national surveillance done. Limited 
studies were conducted since 1960s, but they do not reflect the current situation of 
DR in Sudan. 
 
Background: 
 
The total number of smear positive newly diagnosed TB cases reported from 20 states 
out of the 26 states in the year 2000 was 12.248, the number of relapse cases was 
2,081 during the same year. The total number of smear negative cases was 6,264 and 
extra-pulmonary was 3,716. 
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Conversion rate was 82% in DOTS areas in comparison with 59.9% in non-DOTS 
areas. Cure rate was 73%. 
 
The recommended treatment regimens in Sudan for different categories are as 
follows: 
• CAT (1) 2 SHRZ 
6 TH (for new smear positive pulmonary TB patients) 
• CAT (2) 2 SHRZE/ 1 HRZE 
5 HRE (for smear positive previously treated TB patients) 
• CAT (3) 2 STH 
10 TH (for smear negative pulmonary TB and extra-pulmonary patients)  
 
Impact of on the NTP:  
 
Main objectives of the national tuberculosis programme are case finding and 
management. 
 
Implementation of DOT strategy, (if done correctly) has been effective in curing up to 
85% of all TB cases under programme condition. 
 
DR TB is a significant threat to TB control because few effective drugs are available 
against M. tuberculosis (6). In particular the spread of strains resistant to the most 
important drugs, isoniazid and rifampicin, could have serious changes in the 
epidemiology and control of TB. Not only are patients infected with strains resistant 
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to multiple drugs are less likely to be cured, but second-line treatment is much more 
toxic and expensive than treatment of patients with susceptible organisms (7). 
 
From a public health point of view, attempts to introduce second–line drugs for MDR 
– TB in a setting that is unable to guarantee acceptable cure rates of drug-susceptible 
TB cases, will most likely lead to disastrous consequences. Drug-resistance to 
second–line drugs will emerge rapidly, resulting in greater harm than benefit (2). 
The WHO, IUATLD and several worldwide partners in 1994 launched global project 
on anti-TB DR surveillance, the main objectives of that project were: 
 
• To improve the performance of the NTP through policy recommendations  
• To improve the diagnostic capacity of laboratories  
• To revise policy on anti-TB treatment based on the analysis of the results 
• To assess the impact of migration on the prevalence of anti-TB DR. 
 
Data from 35 geographical settings confirmed that DR TB was significant.  MDR-TB 
existed in all countries surveyed. Some of these settings had a prevalence of MDR-
TB in new cases exceeding 4% (8). 
 
Exact situation of TB drug resistance in Sudan is unknown, data available from NTP 
regarding the 2000 treatment result’ report were as follow: 
 
• The total number of cases was 12.248 in the year 2000 
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• The number of cured patients was 6419 (52.4%) 
• The total number of deaths was 493 (4%) 
• The total number of failure cases was 214, the failure rate is 1.7 %   
• The total number of defaulters was 1415 (11.6%) 
It is expected that a large proportion of the failure cases are resistance.  
Failure to respond to treatment may also be due to: 
• Non-compliance 
• False positive smear  
• Chronic excretors of sensitive strains 
 
In a study done in northern Sudan from August 1961 to January 1965, tests of 
sensitivity to H, S and para-aminosalicylic acid were done on 401 strains of M. 
tuberculosis. Resistance to one or more drugs was found in 28% of 181 strains from 
patients who claimed not to have received previous chemotherapy. Of the 180 strains 
from patients with a definite history of previous chemotherapy, 85% were resistant. 
The proportion of resistant strains in all 401 patients was 54% indicating the 
magnitude of the therapeutic problem facing the physicians (9). 
 
We can observe the high rate of drug resistance in this study although it had been 
conducted after few years since the introduction of the anti-TB chemotherapy.  
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LITERATURE REVIEW 
 18
 
 
Global TB epidemiology 
 
 Increase in TB incidence occurs all over the world, but most alarmingly in the 
developing countries where it is still one of the major causes of deaths. In 
industrialized countries, more than 80% of individuals infected with M. tuberculosis 
are over the age of 50. By contrast in the developing countries, over 75% of TB cases 
are found in individuals below the age of 50, the most economically productive age 
group (2). 
 
After the discovery of the chemotherapy there was steady decline in TB morbidity, 
but in the last 20 years the number of infection is increasing each year (i.e. in excess 
of what would have been observed had the previous rate of decline continued (3, 10, 
11). 
 
A combination of social, economic, historical and demographic factors including 
urban homelessness, intravenous drugs abuse, alcoholism, poor nutrition, growing 
neglect of tuberculosis control programmes and mostly the AIDS epidemics, are 
thought to be responsible for this reversal (12). 
 
Demographic factors have played a major role in the global re-emergence of TB. The 
populations size, mostly of poor countries has increased, the highest incidence of TB 
across the world are in central Africa and Southern Asia, particularly in India, where 
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the population increase is known to be the most rapid. Current annual population 
growth in these countries is about 100 million, which means that global TB incidence 
in absolute numbers will continue to increase by around 100.000 cases every year (2). 
 
An important factor associated with increase TB infection in many countries is  HIV 
and acquired immune deficiency syndrome (AIDS). It is known that co-infection with 
HIV infection increases the risk of TB infection developing into disease by a 100 
fold. TB patients infected with HIV become severely ill and the rate of death among 
them is higher compared with non-HIV infected patients. In addition HIV infection 
elevates the risk of development of the disease from the primary infection. So HIV 
increases the incidence of TB especially in young and middle- aged adults (2, 13, 14).  
It is difficult to diagnose tuberculosis in HIV- infected patients, and the disease 
rapidly leads to death if not treated (15). 
 
Prior to the onset of the AIDS epidemic the incidence of TB in the United States, and 
most other industrialized countries, had declined steadily for almost 40 years. During 
the period 1984-1991, over 39.000 excess cases of the disease were identified in the 
United States by the Center of Disease Control (CDC) in Atlanta (3), and the majority 
attributed to infection with HIV (16). Similar trends were reported in several 
European countries, and TB in young adults is now considered as a sentinel disease 
for AIDS in this settings (17). 
 
 20
In developing countries the situation is even worse. Nearly 80% of the million people 
in the world, believed to be annually infected with HIV and M. tuberculosis, are 
living in Africa, especially sub-Saharan Africa (1, 18). It has been estimated that 
230.000 of the 305.000 excess cases of TB attributable to HIV in 1990 occurred in 
Africa (19).  
 
Social and economic factors have played a major rule in the epidimiology of TB in 
the world. Inequity and poverty in the poor countries contribute to the higher 
prevalence of the disease in those countries. It is known that TB rate is higher in 
lower socio-economic groups where the bad living conditions like unemployment, 
overcrowded living conditions and hunger play an important role for spread of 
infection and development of the disease (2, 13, 20). 
 
TB control programmes have failed to reduce TB transmission. Lack of political 
commitment and inadequately funded programmes increase the pool of chronic cases. 
Due to improper health facilities TB patients who have interrupted their treatment, 
transferred from a curable patients to failure patients, which is the critical situation for 
development of DR strains, and transmission of that strains among the population 
(13). 
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Drug-resistant TB: 
 
Primary resistance refers to the resistance observed following infection with an 
isolate of M. tuberculosis that is already resistant to a given anti-tuberculosis agent, 
where as secondary, or acquired, resistance corresponds to drug resistance emerges 
during treatment. The latter is generally the result of poor compliance on the part of 
the patient, or poor conception of the regimen and inadequate supervision on the part 
of the physician (15, 21). 
 
Adult patients can be infected with primary drug-resistant strains or acquire resistance 
to anti-tuberculosis drugs during the treatment. Usually children have primary 
resistance, as they get infected from an adult source with drug resistant TB (22, 23). 
  
WHO and International Union Against Tuberculosis Lung Disease recommended to 
use the terms drug resistance among new cases and drug resistance among previously 
treated cases. That is because the terms acquired drug resistance and primary drug 
resistance suggests that the exact causative nature of drug resistance is known. But 
sometimes patients do not disclose prior treatment for TB due to several reasons. On 
the other hand, patients who failed to be cured by ordinary anti-TB treatment may do 
so because their strain was initially resistant to anti-TB drugs and not because it 
acquired resistance during the treatment (24). 
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Drug resistance among new cases (formerly: primary drug resistance) is the presence 
of drug-resistant strain of M. tuberculosis in a newly diagnosed patient who never 
received anti-TB drugs or has received them for less than one month (24). 
 
Drug resistance among previously treated cases (formerly: acquired drug resistance) 
is that found in a patient who has previously received at least one-month therapy with 
anti-TB drugs (24). 
 
The emergence of strains of M. tuberculosis that are resistant to anti-mycobacterial 
agents are a worldwide problem whose global magnitude is not well described. The 
WHO and the IUATLD reviewed 63 surveys of resistance to anti-TB drugs that were 
performed between 1985 and 1994. Rates of primary resistance to H, administered as 
a single agent, ranged from 0 to 16.9% (median rate, 4.1%); to S, 0.1%-23.5% 
(median, 3.5%); to R, 0-3.0% (median, 0.2%); and to E, 0-4.2% (median, 0.1%). The 
rates of acquired resistance to these agents, which were higher than those of primary 
resistance, were as follows: H, 4.0%-53.7% (median rate, 10.6%); S, 0-19.4% 
(median, 4.9%); R 0-14.5% (median, 2.4%); and E, 0-13.7% (median, 1.8%). The 
highest rates of MDR have been reported in Nepal (48.0%), Gujarat, India (33.8%), 
New York City, (30.1%), Bolivia (15.3%), and Korea (14.5%) (25, 26). 
 
Resistance of mycobacterial strains to anti-TB drugs was noticed since the 
introduction of S in 1943, when used as mono-therapy for the treatment of TB. It is 
easy to understand why, as the frequency of mutation leading to S resistance is now 
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known to be 10-6.  It is not uncommon for patients with pulmonary disease to harbor 
such numbers of tubercle bacilli in a single lesion (27). Consequently, regimens 
where developed in which S was combined with another drug, as it was correctly 
reasoned that the S–resistant mutants present in the population would remain 
susceptible to the second drug (28). So the development of multi-drug regimens since 
1950s offered a way to overcome the problem. The frequency of the transmission of 
DR organisms was thought to be low until the early 1990s when outbreaks of MDR 
TB were reported in patients with HIV infection in the United States and Europe, and 
the problem received inter-national attention (5, 20, 29-31). 
 
Multi-drug resistance (MDR): 
 
One of the most alarming consequences of dual infection with HIV and M. 
tuberculosis has been the emergence of MDR strains, which cause a potentially 
untreatable form of TB (32, 33). Small epidemics of the transmission of MDR-TB in 
institutions, such as hospitals, HIV clinics and prisons, involving both HIV- infected 
individuals and staffs, were reported in USA and in a much smaller scale in some 
European countries (34-36). The mortality rates were extremely high (70-90%), and 
the median survival time from diagnosis of MDR-TB was less than 16 weeks (34). 
 
The current definition of MDR TB, involves resistance to at least H and R, the key 
components of short course chemotherapy, although resistance to other anti-TB 
agents is not uncommon in certain areas (21, 37). 
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Outcomes of MDR TB is usually poor with high mortality rate. Persons with MDR 
TB were reported to have alveolar infiltrates, cavity pulmonary lesions, reticular 
interstitial infiltrates and respiratory insufficiency than those infected with susceptible 
strains (38). 
 
DR is more prevalent among refugees and immigrants from countries with a poorly 
functioning control programme. For instance, in a study conducted in California, it 
was found that the case rate of DR disease was 30 out of 100.000 amongst 
immigrants from South-East Asia (39). Whereas in UK, the few cases of MDR-TB 
which have been recorded were amongst Kurdish refugees (40, 41) or immigrants 
from the Indian subcontinent (42). 
 
      MDR TB should be suspected in the following cases: 
• Patients in hospitals or prisons known to have had outbreaks of MDR TB. 
• Patients from geographic areas where MDR TB is common. 
• Patients known to be at high risk for MDR TB, those infected with HIV or having 
AIDS, intravenous drug users or homeless. 
• Patients who have relapsed after prior treatment or having a history of previous 
treatment for TB (43, 44).  
 25
 
 
Drug resistance in developing countries: 
 
DR in developing countries is a good indicator of the efficacy of the national TB 
programme. Resistance was common in countries applying substandard regimens but 
decreased as short course chemotherapy was more widely implemented. For instance, 
in Algeria the level both of primary and acquired resistance declined by 3-4 folds 
during the period 1965-1990 (44), as the result of the rational deployment of 
resources and improved control programmes. Reliable figures from longitudinal 
studies of resistance levels in developing countries are not available, although it is 
generally believed that the situation is deteriorating due to the impact of the HIV 
epidemic, deteriorating socioeconomic conditions and instable drug supply (45). In a 
recent report, increased prevalence of MDR-TB was described in the republic of 
Djibouti, where the situation was compounded by war, famine and HIV (46). 
 
 26
Molecular basis of drug resistance: 
 
M. tuberculosis is naturally resistant to many anti-biotics; particularly to those 
belonging to the B-lactam, macrolide or tetracycline families.This may be due to its 
highly lipophilic cell envelope acting as an efficient permeability barrier (47, 48). 
 
Drugs active against M. tuberculosis are classified into two groups: first and second-
line. There are currently five first-line drugs and, with the exception of E they are all 
bactericidal and display low levels of toxicity.  
Second line drugs are generally less efficacious and levels of toxicity are generally 
higher and reserved for the treatment of cases with resistance to first-line agents.  
Resistance of M. tuberculosis to anti-TB drugs is a man made amplification of a 
natural phenomenon. Wild strains of M. tuberculosis that have never exposed to anti-
TB drugs are almost never resistance, though natural resistance to specific drugs e.g. 
pyrazinamide has been documented for M. bovis.   
However, regarding DR development the interest focuses on the random process of 
genetic mutations that leads to the emergence of clinical resistance to anti-TB 
treatment (49). The mechanisms are chromosomal caused by one or more mutations 
in independent genes.  
  
During bacterial multiplication, resistance develops through spontaneous mutations at 
different gene loci at a low but defined frequency in the wild type strain. Mutations 
resulting in resistance of M. tuberculosis to R occur at a rate of 10 –10 per cell division 
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and lead to estimated resistance prevalence of 1 in 108 bacilli in drug-free 
environments. The rate for H and S is 10-7 to 10-9, resulting in resistance in 1 in 106 
bacilli (50). Thus resistant organisms (or mutants) evolve in the absence of anti-
microbial exposure, but they are diluted within the majority of drug-susceptible M. 
tuberculosis.  
When two or more drugs are administered together the value becomes the product of 
the individual probabilities to each drug. The mutation rate for resistance to more than 
one drug is calculated by multiplying the rates for the individual drugs. For example 
the likelihood of spontaneous mutations resulting in resistance to both H and R is the 
product of individual probabilities, i.e. 1 in 1014 (106x108) The probability of MDR 
development is dependent on the number of mutant bacilli (23, 51, 52). This is in fact 
one of the essential reasons for the use of multi-drug regimens in the treatment of TB 
(53, 54). 
 
An untreated cavity has 107-1010 organisms, many of which are resistant to single 
drug. Exposure to a single drug, due to: irregular drug supply, poor drug quality, 
inappropriate prescription and/or poor adherence to treatment suppresses the growth 
of bacilli susceptible to that drug but permits the multiplication of drug-resistant 
organisms. If the single anti-TB therapy is replaced by another effective drug, the 
second drug will kill bacilli sensitive to the second drug but the small number of 
mutants resistant to the second drug will survive. As a result mutants resistant to two 
drugs are selected, resulting in acquired drug resistance. Transmission of such bacilli 
to other persons may lead to disease, which is drug resistance from the outset, a 
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phenomenon known as primary resistance. Every drug active against M. tuberculosis 
is found to select for resistance (55-57). 
 
Resistance to isonized: 
 
Together with R, H comprises the backbone of the current short course chemotherapy 
regimen used to control TB. It shows remarkable specificity being active only against 
members of the M. tuberculosis complex (M. africanum, M. bovis and M. 
tuberculosis). 
 
It is action as anti-TB agent is mediated by the haem-containing enzyme, catalase 
peroxidase, encoded by the katG, (58, 59) which is also implicated as a mycobacterial 
virulence factor (59, 60). There is now a large body of evidence, both biochemical 
and genetic demonstrating that H undergoes a peroxidative reaction catalyzed by 
catalase peroxidate, in which it is transformed into an exquisitely potent bactericial 
derivative (59, 61-63). The precise action of this compound remains obscure. 
Although it has been proposed that H may be converted into isonicotinic acid, an 
analogue of nicotinic acid the precursor for nicotinamideadenine dinucleotide (NAD) 
synthesis. It seems that its principal site of action is mycolic acid biosynthesis (63). A 
new gene, inhA was isolated recently which encodes an enzyme involved in mycolic 
acid production, however as all mycobacteria examined contain inhA and produce 
mycolic acids, it is conceivable that there may be another target, confined to M. 
tuberculosis, as this would explain the specificity of H. 
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Shortly after introduction of H, resistant mutants of M. tuberculosis were isolated (62, 
64). These often lack catalse-peroxidase, or produced weak activity, and displayed 
reduced virulence in the guinea-pig model. It is now known that this can result from 
deletion or mutation of the katG gene, and that lowering enzyme activity results in 
DR (59, 65). When there is an over production of catalase- peroxidase, susceptibility 
to H is usually increased. Roughly 60% of H resistant mutants have mutations in the 
katG locus, whilst 20% have undergone modifications of their inhA genes (66). Some 
highly resistance strains have mutations at both sites and others have no known 
defects, suggesting that a third resistance mechanism may also exist. 
 
The potential mechanisms of resistance to isoniazid include: 
 
• Mutations that inhibit the mycolic acid biosynthesis. 
• Mutations in the biosynthesis pathway that would inhibit the assembly of the     
catalase-peroxidase of M. tuberculosis to an active compound. 
• Inactivation of an inhibitor of NAD glycohydrolase, which depletes intracellular      
concentration of NAD. 
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Rifampicin  
 
R interferes with transcription and elongation of ribonucleic acid (RNA) by binding 
to the deoxyribonucleic acid (DNA)-dependent polymerase (67). Development of 
resistance to R follows a ‘‘single-step’’ high-level resistance pattern (68), with 
mutants arising spontaneously in strains not previously exposed to the antibiotics at a 
frequency of 10-8 (69). Resistance to Ris associated with specific mutations involving 
a core region of 27 amino acids in the ß-subunit of the RNA polymerase (70-73). The 
majority of the mutations (> 75%) affects only two positions, His-526 and Ser-531. 
Complementation studies have shown that such mutations results in R resistance: a 
plasmid carrying a mutated rpoB of E.coli confered resistance to a susceptible strain 
(67), and a plasmid carrying the wild type rpoB of M. tuberculosis or M. leprae 
partially restored susceptibility to R in a resistant mutant of M. smegmatis (47). 
 
Several groups have confirmed that mutations in rpoB are present in >97% of more 
than 200 R resistant clinical isolates of M. tuberculosis investigated so far (66, 71, 
73). 
 
Resistance to R is rarely found without associated resistance to other drugs. Most 
importantly, R resistance predicts both resistance to H and poor outcome of therapy 
(37, 68, 69). Together with the possibility of targeting a single region of the genome 
for diagnostic purposes, in contrast to the multiple genes involved in resistance to H 
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and to other drugs, makes R a valid surrogate marker for MDR-TB. So detection of 
resistance to R could be used as a surrogate marker for the presence of MDR-TB. 
 
Streptomycin: 
 
S, a broad-spectrum aminoglycoside, was the first antibiotic available for TB control 
and its use in mono-therapy soon led to the emergence of resistant strains. S 
resistance in M. tuberculosis represented an easy target for molecular genetic 
analysis. S interferes with protein synthesis in mycobacteriae by binding to the 16S 
ribosomal RNA causing misreading of the genetic code and inhibition of translation. 
The principal site of mutation is the rpsl gene, encoding ribosomal protein S12, 
whose primary structure has been highly conserved during evolution, where as 
alterations to functionally constrained loops of the 16S ribosomal ribonucleic acid 
(rRNA) that interact with the S12 protein represent a secondary site (43, 47, 74). 
 
Pyrazinamide 
 
There is less knowledge on the mechanism of action of Z than for any other anti-
mycobacterial agent (70). Susceptible M. tuberculosis strains produce the enzyme 
pyrazinamidase, which converts Z to pyrazinoic acid. It is thought that the action of 
pyrazinoic acid is the combined effect of its specific activity and the ability to lower 
the pH below the limits of tolerance of the target organism. There is imperfect 
agreement between loss of pyrazinamidase activity and resistance to Z. 
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Ethambutol 
 
The mode of action of E has not yet been elucidated. Initial reports described the 
binding of E to the cell wall. Later inhibition of arabinogalactan synthesis that is the 
component of the cell wall was presented as the most relevant target. Genetic 
explanation of E resistance is mutation in embCAB gene cluster (74). More recently 
the inhibition of glucose conversion into the precursors used for the synthesis of cell 
wall polysaccharides such as arabinogalactan, arabinomannan and peptidoglycan has 
been proposed. A non-contiguous genomic region has been cloned and presented in a 
preliminary report as containing determinants, which encode the putative target of E.   
 
Risk factors for the development of drug resistance 
 
      The emergence of drug resistance TB in a population has been associated with: 
 
Health systems: 
 
• Lack of drug availability  
• Poor management of TB patients due to lack of, or inadequate treatment 
guidelines. 
• Frequent or prolonged shortage of drug supply in areas with inadequate resources 
or political instability and usage of drugs of unproven quality.  
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Health providers: 
 
• Incorrect management of individual cases. The most common error is addition of 
a single drug to a failing regimen.  
• Improper selection of the appropriate chemotherapeutic regimen due to lack of 
recognition of prior treatment and ignorance of the importance of standardized 
regimens (37, 64). In addition, providers might not monitor patients appropriately 
while on therapy.  
• Unavailability of drugs. 
                                                                                              
Patient’s non – adherence to prescribed treatment  
 
• Social/cultural/political factors such as population movements, rural/urban 
immigration. 
• Social stigmatization, gender differentials and lack of health education. 
• Unstable situation due to war,  imprisonment or poverty (75). 
 
Previous treatment for TB, non-compliance to treatment or failure to complete a 
curative course of therapy are considered to be risk factors for the development of 
acquired drug resistance or resistance among previously treated cases. 
Previous treatment for TB is considered by many authors to be an important risk 
factor for the development of drug resistance (23, 38, 52, 71, 72). 
Non-adherence is difficult to predict from demographic or social characteristics but is 
less likely to occur if directly observed therapy (DOT) is in use (76). Some potential 
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barriers to successful treatment include the need for long term (6 to 12 months) and 
complicated drug regimens, the cost in time and money, long wait in crowded public 
health facilities, contradictory expectations and beliefs between patients and health 
care providers, communication difficulties and transportation. Homelessness, 
alcoholism, drug addiction and substance abuse can predict non-compliance (23, 52).  
 
Finally a crucial element in the emergence of DR is the lack of a properly organized 
system to ensure prompt diagnosis and effective treatment (77). For this reason, the 
level of anti-TB drug resistance in a population is an indicator of the effectiveness of 
a NTP. 
 
Risk factors for development of resistance among new cases: 
 
Contact with a patient who has infectious, drug-resistant TB is a significant factor for 
primary resistance. Transmission of infection depends on several factors like the 
infectiousness of the possible source and the closeness and intensity of the exposure. 
Any person who shares the air space with a patient with MDR TB for a relatively 
prolonged time (e.g., household member, hospital room mate) is at a higher risk for 
infection than those with a brief exposure to a MDR TB patient, such as a one-time 
hospital visitor. Exposure of any length in a small, enclosed, poorly ventilated area is 
more likely to result in transmission than exposure in a large well-ventilated space. 
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HIV infection is another important risk factor for development of primary drug 
resistance (38, 43, 78). Persons with HIV infection are more likely to be infected with 
TB if exposed. The HIV epidemic may have a significant effect on the spread of 
primary drug-resistance in communities with co-existent HIV and DR TB since 
contacts of HIV infected people with M. tuberculosis are more likely to result in 
active disease and more quickly compared with contacts of infected immune-
competent people. This explains the high level of primary DR TB when combination 
of TB, inadequate treatment and HIV infection is observed (48, 71, 72). 
Immuno-compromised conditions other than HIV infection are also important risk 
factors for development of MDR TB. They include conditions requiring prolonged 
high dose corticosteroid therapy and other immunosuppressive therapy, organ 
transplantaion, chronic renal failure, some haematological disorders e.g., leukemia 
and lymphoma and systemic disease of connective tissues.  
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OBJECTIVES OF THE STUDY 
 
General: 
To find the extent of anti-TB DR in Sudan 
 
Specific:  
• To estimate the proportion of DR TB in new cases  
• To estimate the proportion of DR TB in previously treated cases  
• To identify medical, social and demographic factors associated with the development 
of DR TB 
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CHAPTER II 
 
MATERIAALS AND METHODS 
 38
 
Patients and bacterial strains 
 
The study was performed in 3 different districts in Sudan (Khartoum, Gazira, and 
camps for displaced population) on patients with pulmonary TB diagnosed and 
treated in the 3 different districts. 
 
Population at risk was 7.800.000 inhabitants of Khartoum, Gazira states and camps 
for displaced population (according to the last estimation made on 1997) 
 
Target population consisted of TB patients from Khartoum, Gazira states and camps 
for displaced population.  
 
Study sample included patients from Khartoum, Gazira states and camps for 
displaced population with new and previously treated patients diagnosed in the 3 
different areas was selected according to the inclusion criteria. 
 
Inclusion criteria 
 
 1. Stains collected from patients with new smear positive pulmonary TB during a 
five months period (July -December) 2001 in above-mentioned sites. 
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2. Strains collected from patients on re-treatment regimen diagnosed as failure, 
relapsed or treatment after default during a five months period (July – December) in 
2001 in above-mentioned sites. 
 
1. All strains were collected from patients before the start of treatment with anti-TB          
drugs. 
 
Study type  
 
We performed a case control study in the NTP’s clinics in the chosen areas in Sudan, 
where suspected patients were identified as pulmonary TB patients by smear 
microscopy testing. Culture of the sputum specimens was performed in the RNL in 
Sudan; drug susceptibility testing was performed in the NIPH, Oslo, Norway 
A case control design was chosen because this type of study is relatively simple and 
economical to carry out and increasingly used to investigate risk factors of disease 
development – DR TB in our case. The study included patients with the disease of 
interest, DR TB and a control group, patients with drug susceptible TB. 
 
Sample size 
 
According to WHO and IUATLD recommended strategies for sample collection for a 
survey on the prevalence of anti-TB DR, the calculation of an appropriate sample size 
should be based on the following: 
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Expected prevalence of resistance to R or to the drug of the lowest known level of 
resistance, from previous available data or based upon data available from the NTP.  
Precision should be as accurate as possible but calculation needs to ensure a sample 
that is logistically feasible to obtain. 
The recommended level of confidence around the estimated prevalence is 95% 
The calculated sample size needs to be increased by 5%-20% to account for expected 
losses. These include patients whose culture are contaminated or does not grow and 
patients whose susceptibility testing does not give interpretable results. 
                 
 
We used formula (student formula) for sample size calculation N= Z2pq/d2 
N – number of observations needed 
P – estimated prevalence 
Z=1.96  
d = allowable error (0.05-0.08) 
q=1-p 
 
Since there is no recent study conducted in Sudan regarding the prevalence of M. 
tuberculosis strains resistant to anti-TB drugs I have based my estimation upon the 
results of the study done in Ethiopia in 1997, assuming that it has the similar situation 
as in Sudan regarding TB prevalence. 
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In that study 107 isolates were identified as M. tuberculosis had been investigated for 
drug susceptibility, it was found that, 44% strains were resistant to H, 28% were 
resistant to streptomycin, 12% were resistant to R and 2% were resistant to E (79). 
According to the WHO and IUATLD recommendations we calculated our study 
sample taking R to base our calculation on. 
According to data available from the study, we estimated that p=0.12 for any type of 
resistance and we would like to have a = 0.05. 
 Number of observations needed is;  
N= (1.96) 2(0.12x0.88)/0.052 = 162 
The calculated sample size was increased by (5%-20%) to account for expected 
losses. The final sample size consisted of 170 patients.  
 
Collected sample 
 
A total of 170 M. tuberculosis strains isolated from patients with pulmonary TB in the 
3 chosen areas in the study during July – December 2001 were cultivated on 
Lowenstein-Jensen media and forwarded to the NIPH, reference laboratory for 
tuberculosis, for further analysis. Twenty-six strains were either contaminated or died 
during transportation. The final sample size consisted of 144 strains.  
 
Representativeness of the samples:  
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We ensured representativeness of the target population by including in the sample all 
newly diagnosed patients who fulfill the inclusion criteria. 
During the planned period of data collection all patients with newly diagnosed 
pulmonary TB and all patients with previously treated pulmonary TB diagnosed in 
the NTP clinics of the 3 different areas included in the study. 
The above-mentioned states was chosen accordingly: Khartoum State as a city with a 
large number of inhabitants (4.600.000) with a higher rate of patients who interrupted 
their treatment and many failure cases (problem of capital city with a lot of 
demographical changes) 
Gazira State as an example of stable Population City with 1.200.000 inhabitants 
Camps for displaced populations where they represent around 2 millions inhabitants 
coming from the southern and western parts of Sudan (for war, political instability 
and employments reasons) 
 
The sample size was collected during fixed period of time as it is described in the 
inclusion criteria. Strains were collected from smear positive cases of pulmonary TB. 
Collection of sputum for smear examination was performed routinely for all patients 
when suspected for TB. Collection of sputum for culture examination was done for 
the study though it was not performed routinely for all TB patients. 
 
Data collection 
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Data collection forms of the 144 patients were filled in order to identify factors 
associated with the development of DR. (Appendix) 
 Social factors such as the marital status and smoking habit, medical factors such as 
the history of previous treatment with anti-tuberculosis treatment and demographic 
factors such as the age and gender were analyzed. 
 
 
. 
Variables 
 
Dependent variable: 
 
Drug resistance 
Definitions: Resistance of M. tuberculosis strains to anti-TB drugs according to 
susceptibility test by BACTEC method  
Scale of measurement: 
1. Susceptible 
2. Resistance 
 
 Independent variables:  
 
1. Patients categorization according to the results of previous treatment  
1. New case 
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2. Relapse  
3. Failure 
4. Treatment after default 
 
  2. Age  (Expressed in years) 
 
   3. Gender                                                                                   
1. Male  
2. Female 
 
    4. Address 
1. Khartoum 
2. Gazira 
3. Camps for displaced population 
 
     5. Origin of patients (Sudanese people are culturally divided geographically according    
to their regions of origin into 4 groups: north, south, east, west and central part of Sudan)                    
1. North 
2. South 
3. West 
4. East 
5. center 
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6. Weight (measurement of weight)  
   Expressed in kilograms 
 
7. Height       (measurement of height) 
    Expressed in centimeters 
 
   8. Occupation 
   1. Student 
   2. Labor 
   3. Governmental employee 
         4. Running small business 
   5. Running big business 
    6. Employee in private sector 
    7. Un-employee 
     8.  Housewife 
 
    9. Marital status (Defined in terms of legal status)  
1. Single 
2. Married  
3. Widowed 
4. Divorced 
 
      10. Education                                                                              
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      1. Illiterate (level of education) 
      2. Literate 
 
     11. Crowded living conditions (Mean number of persons per room in housing 
condition)                                                                                                    
         (Number of persons per room) 
                 
     12. Smoking                                                                   
1. Smoker 
2. Non-smoker 
                                 
      13. Contacts with TB patient (TB among relatives or persons living or working 
together)  
       1. Household contact 
       2. Community contact 
       3. Unknown  
 
      14. HIV status  (When TB patients are not adequately treated and level of     
      acquired resistance is elevated, co-existence of HIV could be responsible for the     
      rapid spread of tuberculosis ) 
     1. Positive 
     2. Negative 
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     15.  BCG vaccination 
     1. Present 
     2. Absent 
 
     16. Symptoms of the disease 
           1. Present 
           2. Absent 
 
    17. Duration of the symptoms  
    Expressed in weeks 
 
Bacteriological methods used in the study 
 
Zeil-Neelsen staining (acid-fast staining procedure) was used for smear microscopy to 
identify smear-positive pulmonary tuberculosis cases. 
We used Lowenstein-Jensen (L-J) culture medium.  
Identification of the strains was based on the niacin production test and nitrate 
reduction test.  
For strain susceptibility testing radiometric drug susceptibility test, BACTEC (Becton 
Dickinson Diagnostic System, Towson, MD, USA) was performed. 
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Procedure for Zeil-Neelsen staining: 
 
The numbered slides were placed on a staining rank in batches (maximum 12), 
ensuring that slides do not touch each other. 
The entire slide was flooded with Zeil-Neelsen carbolfuchsin, which has been filtered 
prior to use, or each slide was covered with a piece of filter paper if unfiltered 
carbolfuchsin was used. 
The slide slowly was heated until it was steaming, Avoiding boiling. The steaming 
was maintained for three to five minutes using low or intermittent heat. each slidewas 
rinsed individually in a gentle steam of running water until all free stain was washed. 
The slide was then flooded with the decolourising solution for a maximum of three 
minutes. 
The slide was thoroughly rinsed with water. Excess water was removed from the slide 
and the slide flooded with counter-stain for 60 seconds and rinsed thoroughly with 
water. Excess water was drained from the slide and the smear allowed to air dry (80). 
 
Procedure of culture using Lowenstein-Jensen medium 
 
We used Sodium hydroxide (NaOH) (modified Petroff) method for homogenization 
and decontamination. 
Procedure:  
To xml of sputum, we added 2xml of 4% NaOH, tightened cap of container and 
shacked to digest, let it stand for 15 minutes at room temperature with occasional 
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shaking, centrifuged for 15 minutes, poured off the supernatant, added 15ml sterile 
saline or distilled water and resuspended the sediment, centrifuged at 3 000 x g for 15 
minutes, decanted the supernatant and inoculate onto culture medium immediately 
(80). 
 
 
Identification tests: 
 
Niacin production test: 
 
All mycobacteria produce niacin, however, only M. tuberculosis, M. simiae and 
occasional strains of M. africanum, M. bovis, M. marinum and M. chelonae lack the 
enzyme necessary to further convert the niacin to niacin ribonucleotide. Thus the 
determination of whether niacin has accumulated in the culture medium is a valuable 
differential test in identifying these species of mycobacteria, particularly M. 
tuberculosis. Reagent-impregnated filter paper strips have been developed to replace 
cyanogens bromide, a highly toxic substance. The development of a yellow color in 
the test medium incubated with a reagent strip is indicative of niacin accumulation 
and a positive test (81). 
 
Nitrate reduction test   
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Only a few species of mycobacteria, notably M. tuberculosis, produce nitroreductase, 
which catalyzes the reduction of nitrate to nitrite. The development of a red color on 
addition of sulfanilic acid and N-naphthyleth-lenediamine to an extract of the 
unknown culture is indicative of the presence of nitrite and a positive test (81). 
 
Strain susceptibility testing  
 
We tested susceptibility of M. tuberculosis strains towards four of the first line anti-
TB drugs: H, R, S and E. Z was excluded because it is difficult to measure 
susceptibility to it using the BACTEC method and it is thus excluded from the drugs 
that recommended by WHO/IUATLD to estimate DR in the surveyed regions. 
 
Susceptibility test to anti-TB drugs was performed in the NIPH using radiometric 
drug susceptibility test, BACTEC Becton Dickinson Diagnostic System, Towson, 
MD, USA) (82, 83). 
 
These drugs were chosen because they have been widely used through out the world 
and their susceptibilities can be reliably measured by standardized BACTEC method.  
In 1975 radiometric detection of metabolic products of M. tuberculosis was reported. 
The principle was thereafter used for the detection of growth of tubercle bacilli in 
selective media containing 14 C -labelled-substrate. The resulting release of 14 C CO2 
was measured automatically using an ionization chamber (BACTEC). 
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The system is a modification of the conventional proportion method. Instead of an 
agar base the test uses middlebrook 7H12 broth with a radiolabeled fatty acid 
substrate. BACTEC 460 method uses standard sputum concentration techniques and a 
combination of polymyxin B, amphotericin B, carbenicillin and trimethoprim to 
minimize contamination by non-mycobacterium organisms. This decontamination 
treatment allows the specimen to be inoculated directly into middlebrook 7H12 broth 
media containing 14C-labeled palmitic acid. 
                 
Growth of M. tuberculosis in the media releases 14CO2 in the bottle that is then 
measured radiometrically. The amount of growth, indicated by changes in the growth 
index (ãG1) in the media with known drug concentrations compared to that in the 
control bottle, has been correlated to the presence or absence of resistance of >10% of 
the inoculums. If an isolate grows beyond a specific growth index compared with the 
control it is considered resistant to that specific agent (83, 84). 
 
The concentrations of the anti-TB drugs used for the test were as follows: 
H, 0.2 µg/ml; R, 2.0 µg/ml; E, 7.5 µg/ml; and S, 6.0 µg/ml 
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Statistical analysis 
 
 Data sorting and patients distribution into case and control groups was performed 
after laboratory testing of all collected M. tuberculosis strains. 
 SPSS was used for all the statistical analysis.  
Association between categorical variables was assessed by the x2 test. Differences 
between groups were expressed as Odds ratio (OR) with 95% confidence intervals 
(95% CI). Student t-test was used to test for differences in means of continuous 
variables. P value of < 0.05 was chosen as the level of significance. 
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Definitions 
 
Cases were patients whose strains of M. tuberculosis are resistant to at least one of 
the first line anti-TB drugs  
 
Controls were patients included in the study according to the inclusion criteria, 
whose strains of M. tuberculosis are susceptible for anti-TB drugs. 
 
New cases were patients who have not been previously treated for TB or treated for 
less than one month. 
 
Previously treated cases were patients with a history of previous anti-TB treatment 
for at least one month. 
        
Resistance to each of the first line anti-TB drugs was defined according to the results 
of susceptibility tests by BACTEC method. 
The first line anti-TB drugs:  
Isoniazid (H), Rifampicin (RH), Pyrazinamide (Z), Ethambutol (E), Streptomycin (S) 
            
Any kind of resistance: was defined as resistance to at least one of the first line anti-
TB drugs.  
 
 Poly-resistance was resistance to more than two first line anti-TB drugs.  
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 MDR was defined as resistance to both H and R with or without resistance to other 
agents. 
 
 Drug resistance among new cases: (formerly acquired drug resistance) was defined 
as presence of a resistant strain of M. tuberculosis in a patient who, in response to 
direct questioning, denied having had any prior anti-TB treatment (for more than one 
month) and where there was no documented evidence of such treatment. 
  
Drug resistance among previously treated cases (formerly acquired drug 
resistance) was defined as resistance of a  M. tuberculosis strain to anti-TB drugs in a 
previously treated patient. 
Previously treated cases: Are patients with a history of previous anti-TB treatment 
for at least one month. This includes patients in one of the following groups: 
 
• Patients who become smear positive again after having been treated for TB and 
declared cured after the completion of their treatment (relapse cases).  
• Patients who are having treatment for smear positive pulmonary TB and who 
remain or become smear positive again at five month or later during the course of 
treatment (treatment failures). 
• Patients who have interrupted their treatment for more than two months after 
having received a total of at least one month of anti-TB treatment and who return 
with bacteriologically confirmed TB (return after default). 
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• Patients who continue to be smear positive after the completion of a re-treatment 
regimen (chronic cases). 
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CHAPTER III 
 
RESULTS 
 57
 
 
 
Drug resistance of the M. tuberculosis strains 
 
A total of 170 strains collected from patients with smear positive pulmonary 
tuberculosis in the 3 different places in Sudan (Khartoum state, Gazira state and 
camps of displaced population) were identified as M. tuberculosis. Twenty-six strains 
were excluded from the susceptibility testing since they were either contaminated or 
failed to grow when sub-cultured.  Out of the remaining, 93 strains were from new 
cases and 51 strains were from previously treated cases. All strains were tested by the 
BACTEC method for susceptibility to the first line anti-tuberculosis drugs: H, R, S. 
and E. The susceptibility pattern to H, R, S and E of the 144 M. tuberculosis strains is 
represented in (Table1). 
 
It is important to mention that the strains were collected mainly from the chest 
referral hospitals, where most chronic cases are usually admitted, like Abu-Anga 
hospital in Khartoum. This is known as a TB hospital and patients from all over the 
country are usually referred to that hospital when they have failed to be cured by 
ordinary anti-TB treatment. 29 of the 144 patients were from Abu-Anga hospital 
(20%)  
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Seventy- two (50%) of the strains were susceptible to at least one drug, and 72 (50%) 
were resistant. Mono-resistance to S was present in a high number of both new and 
previously treated patients. When we excluded S resistance, we found that 100 
(69.4%) of the strains were susceptible to at least one of the other remaining drugs, 
and 44 (30.6%) were resistant. 
 
The highest rate of mono-drug resistance was observed for S in both groups of 
patients (new and previously treated patients). 22 (23.6 %) strains collected from new 
and 8 (15.6 %) of strains collected from previously treated patients were mono-
resistance to S (Table 1). 
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Table 1: Drug susceptibility pattern of H, R, S and E of the M. tuberculosis strains 
isolated from 144 patients with pulmonary TB in Khartoum, Gazira and camps for 
displaced population. 
 
NO. PREVIOUSLY 
TREATED CASES 
H 
 
R S E NO.  NEW CASES F R TAD T TOTAL
R R R R 0 10 3 8 21 21 
R R S S 0 2 1 0 3 3 
R R R S 2 2 1 2 5 7 
R S R S 8 0 0 1 1 9 
R S S S 1 0 0 0 0 1 
S R R S 1 0 0 0 0 1 
S S R S 22 0 1 7 8 30 
S S S S 59 1 1 11 13 72 
 
S:  susceptible              R: resistance 
      F: failure                      R: relapse                      TAD: treatment after default 
T: total of previously treated patients 
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 Resistance to four drugs was detected in 21 strains (15%). Mono-drug resistance to H 
and S was detected in 1 and 30 strains respectively. Resistance to only two drugs was 
found in 3 strains (for H and R), 1 strain (for S and R) and 9 strains (for H and S). 
Resistance to 3 drugs was detected in 7 strains. 31 strains (22%) were MDR. Twenty-
one strains (14.6%) were resistant to E, resistant to E was only seen in MDR. With 
the exception of only one strain, all strains resistant to R were MDR.  
With exception of 2 new patients, all MDR cases were found among previously 
treated cases. Most MDR strains (90%) were also resistant to S and 68% of them 
were resistant to E.  
 
Strains were collected from 93 (64.6 %) newly diagnosed patients, and 51 (35.4 %) 
previously treated patients (table 2).   
 
Among the 93 strains collected from new cases, 34 (36.5%) strains were resistant to 
at least one drug. Out of the 51 strains collected from the previously treated cases 38 
(74.5%) were resistant to at least one drug.  
 
The highest rate of drug resistance was observed for S and H in both groups of 
patients (new and previously treated patients), with 33 (35%) and 35(69%) of strains 
collected from new and previously treated patients were resistant to S respectively. 
Eleven (12 %) and 30  (59%) collected from new and previously treated patients were 
resistant to H respectively (Table 2). 
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Table 2. Drug resistance pattern of H, R, S and E of the M. tuberculosis strains according 
to first or previous treatment. 
 
Resistance to: Number of new cases 
 
Total 93 (%) 
Number of previously treated 
cases 
Total 51 (%) 
             H 11(11.8) 30 (58.8) 
             R 3 (3.2) 29 (56.8) 
             S 33 (35.4) 35 (68.6) 
             E - 21 (41.1) 
   Single drug 34 (36.5) 38 (74.5) 
        MDR 2 (2.1) 29 (56.8) 
 
 
Strains were collected from three different areas in Sudan: Khartoum state, which is 
the capital city of Sudan (population of 4.600.000) Gazira State (population of 
1.200.000) and camps for displaced population (population of 2 millions). In 
Khartoum state 49 (53.8%) out of 91 strains were resistant to any of the tested drugs 
while in Gazira state 14 (56%) out of 25 strains were resistant and in the camps for 
displaced population 9 (32%) out of total 28-tested strains were resistant to any of the 
four tested anti-tuberculosis drugs (table 3). 
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In Khartoum state 24 (26.4%) were MDR, in Gazira state 4 (16%) were MDR and in 
the camps for displaced population 3 (10.7%) were MDR. (Table 3). 
 
Table 3: Drug resistance pattern of the tested M. Tuberculosis strains according to 
patients’ address 
 
Khartoum 
 
Gazira 
 
Camps 
 
 
Total 91 Total 25 Total 28 
 
       Total 144 
 
R. To any drug 49 (53.8%) 14 (56%) 9 (32%) 
 
72 
MDR 24 (26.4%) 4 (16%) 3(10.7%) 31 
 
Factors associated with infection with drug-resistant and multi-drug resistant 
strain of M. tuberculosis 
 
To identify factors associated with the development of DR in the three chosen 
districts in Sudan, demographical, social and medical factors were collected from 
patients were studied in relation to susceptibility patterns of M. tuberculosis strains. 
 
Patients were categorized according to history of previous treatment with anti-TB 
medications. Ninety-three of patients in the study were new cases. Fifteen patients 
were positive for AFBs at 5 months of treatment (failure), and other thirty previously 
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treated patients had interrupted their treatment and six patients had relapsed (Figure 
1). 
Resistant to any kind of drug was present in all patient categories but MDR was 
common among patients treated previously.  
 
Patients previously treated for TB were having a high risk of infection with DR and 
MDR. Thirty-eight of the 72 (52.8%) patients infected with drug-resistant strain had 
an evidence of previous treatment for TB. Thirteen out of the 72 (18.1%) patients 
infected with susceptible strain were treated previously. Previous treatment 
significantly associated with the development of the disease with drug-resistant strain 
(P < 0.0001) (table 4) 
 
Only two among new patients (2.1%) were MDR. Fourteen of the 15 (93.3%) failure 
cases were MDR. Four of the 6 (66.7%) relapse patients were MDR. For those who 
had interrupted their treatment 11 out of 30 (36.7%) patients were MDR. 
 
A total of 29 of the 31(93.5%) patients infected with MDR strains had an evidence of 
previous treatment for TB. Twenty-two of the 113 (19.5%) patients infected with 
non-MDR strains were treated previously. Previous treatment significantly 
contributed to development of the disease with MDR strains (P< 0.0001) (table 5) 
 
The age distribution in the study ranged from 13 to 70 years with the mean age of 40. 
There were 83 patients with age of 40 years or above. 
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Patients in the age group (> 39 years) were having a high risk of infection with both 
DR and MDR strains. Fifty-sex of the 72 (77.8%) patients infected with DR strains 
were 40 years or above. Forty-two out of the 72 (58.3%) patients infected with 
susceptible strain were in this group. Above 39 years was a significant factor 
associated with development of TB with resistant strains. P = 0.012  (Table 4). 
 
Twenty-five of the 31(80.6%) patients infected with multi-drug resistant strain were 
40 years old and above. Fifty-eight of the 113 (51.3%) patients infected with non-
MDR strain were in the same group. Above 39 years was significantly contributed to 
development of TB with a MDR strain. P= 0.003 (table 5). 
 
To explore a possible association between symptoms’ duration and the presence of 
DR we selected the duration of cough as cough is of major importance for 
transmission. We found that the mean duration of cough for patients with MDR TB 
was 51.16 weeks, while the mean duration of cough for TB patients with non-MDR 
strains was 12.45.  
 
Patients with long duration of TB symptoms were having a high risk of infection with 
DR and MDR strains.  Thirty out of the 72 (41.7%) patients infected with drug 
resistant strains were having long duration of cough (more than 20 weeks). Five out 
of the 72 (6.9%) susceptible patients were having long duration of cough. Having 
long duration of cough was highly associated with infection with drug resistant 
strains. P < 0.0001 (table 4). 
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Twenty-three out of the 31 (74.2%) patients infected with MDR strains were having 
long duration of cough (>20 weeks). Twelve of the 113(10.6%) patients infected with 
non-MDR strains had long duration of cough. Having long duration of cough was a 
significant risk risk factor for infection with a MDR strain. P<0.0001 (table 5). 
 
Contact with another TB patient was defined as a known TB patient living in the 
same house, or a known community contact (work place or neighborhood) or no 
known contact. Thirty-five patients had a history of household contact, 24 had history 
of community contact and 85 patients had no history of any kind of contact.  
Contact with TB patient was a strong risk factor for infection with DR and MDR 
strains. Twenty- five out of the 72 (34.7%) patients infected with DR strains had a  
history of household contact with a TB. Ten out of the 72 (13.9%) patients infected 
with susceptible strain had a history of household contact with a TB patient. History 
of a known TB patient living in the same house was significantly associated to 
infection with a DR strain. P = 0.003 (table 4). 
 
Seventeen out of the 31 (54.8%) patients infected with MDR strains had a history of 
household contact. Out of the 113 patients infected with non-MDR strains, 18 
(15.9%) had history of household contact with a TB patient. History of household 
contact with TB patient was strongly associated with infection with MDR strains. P< 
0.0001 (table 5) 
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The weight of the patients in the study ranged from 30 to 70 kilograms. The mean 
weight is 50 kilograms. Forty-two patients weighed 40 kg and less.  
Low weight of patients was strong risk factor for infection with DR and MDR strains. 
Twenty-eight out of the 72 (38.9%) patients infected with resistant strains were 
weighing 40 kg or less. Among the 72 patients infected with susceptible strain, 14 
(19.4%) were weighing 40 kg or less. Having low weight (40 Kg and less) was a 
significant risk factor for infection with resistant strains. P = 0.01(table 4) 
 
Sixteen out of the 31(51.6%) patients infected with MDR strains, were weighing 40 
kg and less. Twenty-six out of the 113 (23.0%) patients infected with non-MDR 
strains were weighing 40 kilograms or less. Having low weight was a strong risk 
factor associated with infection with MDR strains. P = 0.002 (table 5) 
 
Body mass index was calculated to estimate type of body constitution. BMI of the 
patients in this study ranged from 12.4 to 30.61, with a mean of 20.1. Ninety-nine 
(68.75%) patients were under-weight, that is BMI less than 20.0. Forty-one (28.4%) 
had a normal weight, that is BMI between 20.0 and 24.9. Three (2.08%) of the 
patients were overweighed, that is BMI between 25.0 and 29.9. One (0.7%) of the 
patients was obese, that is BMI more than 30. 
 
Among the 144 tested TB patients 98 (68%) of them were males and 46 (32%) were 
females (Figure 2). There was no significant difference in risk of DR (table 4) and 
MDR (Table 5) according to gender of patients. 
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Regarding marital status of the patients, we classified them according to the legal 
status in the country into four different groups: married, divorced, widowed and 
unmarried. Eighty-nine patients were married, 46 were unmarried, 8 were divorced 
and one patient was widowed. (Figure 3) 
Among the 56 single, 28 (38.9%) out of 72 patients infected with DR strains, were 
resistant to any drug and 28 (38.9%) out of the 72 patients infected with drug 
susceptible strains, were susceptible. P =1.000 (Table 4) 
      Eight (25.8%) out of the 31 patients infected with MDR strains, were single.    
      Out of the 113 patients infected with non-MDR strains, 48 (42.5%) were singles.  
      P  = 0.092 (Table 5). 
 
Among the 144 patients, 87 were illiterate and 57 were literate. (Figure 4) 
 Forty-six (63.9%) out of the 72 patients infected by resistant strains were illiterate. 
While out of the 72 infected by susceptible strains, 41 (56.9%) were illiterate. 
P=0.394. (Table 4) 
Twenty (64.5%) out of the 31 patients infected with MDR strains were illiterate. 
While 67 (59.3%) out of the 113 patients infected with non-MDR strains, were 
illiterate. MDR was relatively higher among illiterate but the difference was not 
significant. P= 0.598. (Table 5). 
 
Residence of patients was classified as urban or rural.  Ninety-five patients were 
urban and 49 were rural.    
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Among the 72 patients infected by drug resistance strains, 48 (66.7%) were urban. 
Forty-seven (65.3%) were urban, out of the 72 patients infected by susceptible strains. 
P = 0.579. (Table 4). 
Among the 31 patients infected by MDR strains, 24 (77.4%) were urban. Seventy-one 
(62.8%) were urban out of the 113 patients infected with non-MDR strains. Being a 
rural or urban resident was not a risk factor for infection with MDR strains. P = 0.297 
(Table 5).  
 
Occupation was classified as governmental employee (23), student (15), laborer (35), 
running small business (17), running big business (0), unemployed (18) employee in 
private sector (5) and housewife (31). Drug resistant was found in about the same 
percentages for all occupations except for those who were employees in private 
sector. (Figure 5) 
Among the 72 patients infected by DR strains 4 (5.6%) were employed in private 
sector. While 1 (1.4%) patient was employed in private sector among the 72 patients 
infected with drug susceptible strains. P value = 0.172 (Table 4).  
Three (9.7%) out of the 31 patients infected by MDR strains, were employees in 
private sector, and 2 (1.8%) were employed in private sector among the 113 patients 
infected by non-MDR strains. P = 0.033 (Table 5). 
 
The origin of the patients was classified into 5 groups, northern Sudan 29 patients, 
southern Sudan 35 patients, western Sudan 53 patients, eastern Sudan 7 patients and 
central Sudan 20 patients. (Figure 6) 
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People from west Sudan trended to have a higher rate of resistant to any drug and 
MDR compared to patients from other regions.  
Among the 72 patients infected by DR strains, 29 (40.3%) were from west of Sudan. 
Within the 72 patients infected with susceptible strains, 24 (33.3%) were from west of 
Sudan. P = 0.388. (Table 4).  
Out of the 31 patients infected by MDR strains, 11 (35.5%) were from west of Sudan. 
Forty-two (37.2%) were from west of Sudan out of  the 113 patients infected by non-
MDR strains ( P = 0.863. (Table 5) 
 
Patients housing conditions were classified according to the number of people per 
room. The number of people per room ranged from 1 to 10 with the mean number of 
3 and the mode was 3. Those living in crowded households with 3 or more persons 
per room were 101. There was no significant differences regarding risk of resistant to 
any drug (P=0.363), (table 4). Or MDR (P=0.909), regarding patients crowded or 
non-crowded housing conditions. (Table 5) 
 
Smoking was not a risk factor for development of resistant to any drug or MDR. 
Among the 144 patients, 19 were smokers and 125 were non-smokers. Eleven 
(15.3%) were smokers out of the 72 patients infected by resistant strains where as 8 
(13.2%) out of the 72 patients infected by susceptible strains, were smokers. P=0.460 
Four (12.9%) were smokers among the 31 patients infected by MDR strains. Among 
the 113 patients infected by non-MDR strains, 15 (13.3%) were smokers. P=0.957 
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Thirty-nine patients were BCG vaccinated  and 105 were non-BCG vaccinated. Out 
of the 72 patients infected with DR strains, 13 (18.1%) were BCG vaccinated and 59 
(81.9) were non-BCG vaccinated. Among the 31 MDR strains 4 (12.9%) were BCG-
vaccinated and 27 (87.1%) were not. Non BCG vaccination was significantly 
associated with development of DR P= 0.045 and MDR strains P=0.015 
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Table 4: Demographic and medical characteristics of 144 patients with pulmonary TB in 
relation to infection with resistant and susceptible strains of M. tuberculosis 
 
Infection with drug 
resistant strains 
N=72 (%) 
Infection with drug 
susceptible strains 
N=72 (%) P. Value 
 
Males 
 
48 (66.7%) 
 
50 (69.4%) 
 
0.633 
 
Age 
 
56 (77.8%) 
 
42 (58.3%) 
          
0.012 
Marital status 28 (38.9) 28 (38.9) 1.000 
 
Education 46 (63.9%) 41 (56.9%) 0.394 
 
Previous treatment for 
TB 
 
38 (52.8%) 13 (18.1%) < 0.0001 
 
 
Contact with TB pts 25 (34.7%) 10 (13.9%) 0.003 
 
Duration of cough 
 
 
30 (41.7%) 5 (9.7%) < 0.0001 
 
 
Origin of pateints 29 (40.3%) 24 (33.3%) 0.388 
 
 
Low weight 
 
 
28 (38.9%) 
 
 
14 (19.4%) 0.01 
Residence 
 Urban/Rural 
 
48 (66.7%) 
 
47 (65.3%) 
 
 
0.579 
 
 
Occupation 4 (5.6%) 1 (1.4%) 0.239 
 
 
Housing conditions 48 (66.7) 53 (73.6%) 0.363 
 
 
Smoking 11 (15.3%) 8 (13.2%) 0.460 
 
TB = tuberculosis     OR = odd ratio   95% CI = 95% confidence interval 
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Table 5:Demographic and medical characteristics of 144 patients with pulmonary TB in 
relation to infection with MDR and non-MDR strains of M. tuberculosis 
 
Characteristics 
Infection with multi-
drug resistant 
strains 
N=31 (%) 
Infection with non-
multi-drug resistant 
strains 
N=113 (%) 
 
P. Value 
 
Males 20(64.5%) 78(69%) 0.633 
 
Age 25(80.6%) 58 (51.3%) 0.003 
Marital status 8 (25.8%) 48 (42.5) 0.092 
 
Education 20(64.5%) 67 (59.3%) 0.598 
 
Previous treatment for 
TB 
 
29(93.5%) 
 
22 (19.5%) < 0.0001 
 
Contact with TB pt 17(54.8%) 18 (15.9%) < 0.0001 
 
Duration of cough 23(74.2%) 12 (10.6%) < 0.0001 
 
Origin of patients 11(35.5%) 42 (37.2%) 0.863 
 
Low weight 16 (51.6%) 26 (23%) 0.002 
Residence 
Urban/Rural 24 (77.4%) 71 (62.8%) 0.297 
 
Occupation 3 (9.7%) 2 (1.8%) 0.168 
 
Housing conditions 22 (71%) 79 (69.9%) 0.909 
 Smoking                   
       
       4 (12.9%) 
        
         15 (13.3%)      0.957 
 
TB = tuberculosis    OR = odd ratio    95% CI = 95% confidence interval 
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CHAPTER IV 
 
DISCUSSION 
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In this study we described the prevalence of TB DR among new and previously 
treated patients in Khartoum, Gazira state and camps for displaced population, and we 
identified some of the risk factors associated with the development of DR TB.  
 
Drug susceptibility was tested by the BACTEC method in the National Institute of 
Public Health, Tuberculosis Laboratory in Norway, one of the four DST methods, 
which have been standardized and are widely used throughout the world to measure 
DR of M. tuberculosis (85, 86). 
 
Prevalence of drug-resistance TB in the three chosen areas in Sudan  
 
The extent of the problem of DR TB in Sudan is not known since there is no national 
surveillance done. Limited studies were conducted since 1960s, but they do not 
reflect the present situation of drug resistance in Sudan. A major challenge now a 
days for the NTP and the Tuberculosis Reference Laboratory is to establish a national 
surveillance to determine the resistance pattern to the first line anti-TB drugs in 
Sudan. This study is an explorative pilot study to base the national surveillance on. 
 
Our study showed that resistance to at least one drug among new and previously 
treated cases was 34 (36.5%) and 38 (74.5%) respectively. MDR among new and 
previously treated cases was 2 (2.1%) and 29 (56.8%) respectively. High level of DR 
among previously treated cases is probably due to the fact that most of our strains 
were collected from chest referral hospitals in Khartoum and Gazira states, where 
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most TB patients who had taken anti-TB drugs and failed to be cured end up. (Figure 
7) 
 
MDR was present in 24 (53.8%) strains in Khartoum state, 4 (16%) strains in Gazira 
state and 3 (10.7%) in the camps for displaced population. We can observe that the 
highest level of MDR was found in Khartoum State. Fewer cases of MDR in camps 
for displaced people reflect the good treatment out come, were the DOT strategy is 
vigorously applied. The difference was not significant, but it might be so if we 
increase the sample size. P=0.161 
 
Mono-resistance was found at a high rate for S. 22 (23.7%) and 8 (15.7%) of the 
strains were resistant to S among new and previously treated patients respectively. 
This is not unexpected since S was the first anti-TB drug introduced in Sudan and it 
was widely used by physicians as mono-therapy for the treatment of TB. 
Mono-resistance was at a very low level for H, which has only been used in 
combination with other anti-TB drugs.  
 
Mono-resistance to E or R was not detected. Resistance to R predicted resistance to H 
and served as a marker of MDR. The fact that resistance to R is rarely observed 
without associated resistance to other drugs was confirmed by other studies ((87, 88). 
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Risk factors for the development of drug-resistant TB 
   
High rates of DR among failure and relapse cases were observed in our study. DR TB 
and MDR-TB were significantly associated with a history of a prior treatment period. 
This association might be due to initial infection with DR strains, with unsuccessful 
treatment being the result. However it is more likely that pervious treatment was the 
cause of MDR-TB. Those who had a history of previous treatment may have received 
non-standard regimens or have interrupted treatment. The selection of resistant 
mutants takes place after several regimens have been administered in which cycles of 
killing (when drug is taken) and re-growth (when the drug is stopped) occur (47, 89). 
As the cycles are repeated, there is a stepwise selection favoring the resistant strains 
relative to the susceptible ones. This cyclic process creates an imbalance, causing 
resistance to one drug and later to other drugs and ultimately to MDR. Not 
surprisingly, any DR and MDR-TB were significantly associated with previous 
treatment cases. Previously treated cases, including failures is the richest source of 
DR bacilli in the community (90, 91). They are also an important source of infection, 
since their infectiousness is usually longer than that of new cases (92). However, the 
absolute number of MDR-TB cases is so far small and should not constitute a public 
health threat, provided the TB control programme keep up high cure rates among new 
cases.  
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The administration of SCC under DOT is the cornerstone of curing new cases with 
active disease, and thus to reduce recruitment to the pool of previously treated cases. 
On the other side, if SCC is ineffectively used, an increase in the pool of infectious 
cases, and often DR, will take place (93).     
 
All patients in our study were HIV negative. The data presented in the WHO and 
IUATLD report on drug resistance surveillance suggested that HIV is not an 
independent risk factor for DR, or MDR-TB. Although evidence from different 
settings suggests that HIV-infected TB patients are no more likely to develop drug 
resistance than HIV-negative TB patients (94, 95). Nevertheless, when TB patients 
are not adequately treated and levels of acquired resistance are elevated, co-existence 
of HIV could be responsible for the rapid spread of primary drug-resistant TB. This is 
because HIV infects CD4 + T-cells exclusively. CD4 + T-cells produce interferon –
gamma, which activates macrophages to inhibit intracellular growth of M. 
tuberculosis. As HIV progresses, CD4 + T-cells count drops leading to increased risk 
of primary infection and development of primary TB from primary infection. 
 
Long duration of cough, an indicator of long duration of TB symptoms, was found to 
be strongly associated with MDR and resistance to any drug. Patients might have 
received non-standard regimens or have interrupted treatment prior to their proper 
management. Long duration of cough is a serious situation, since it means long 
duration of infectiousness of patients with resistance strains and that adds to the 
impact of spread and transmission of the disease. 
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In this study low weight of patients was strongly associated with MDR and resistance 
to any drug. That is probably an effect of MDR rather than a primary risk factor since 
long duration of symptoms of the disease and chronic illness are the main causes of 
the loss of weight.  
 
Resistance was higher in known household contact of TB patients than in patients 
with community contacts or without known contacts. Socioeconomic conditions and 
hygiene are amongst the strongest factors influencing favourably the course of the TB 
epidemic in the community (96). Since TB is associated with poverty (97), 
improvements of the social conditions of people should lead to a reduction in the 
incidence of active disease. 
 
In this study, education and male gender trended to be associated with the 
development of DR but the association was not significant. If this reached significant 
when we increased the sample size, it may be explained by that educated people in 
the Sudanese society represents to some extent a higher or a middle class in the 
society, so they are the ones who are most likely to afford access to the health 
services, and thus to drugs. 
There was a trend towards an association between origin in the west of Sudan and 
development of DR. If this reaches significance in further study it may be explained 
by the movements of people from west of Sudan to Khartoum due to war and famine. 
This is the problem of migration in increasing the risk of irregularity in treatment. 
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There is no significant association between the developments of drug resistance or 
MDR and the marital status of the patients.  
This may reflects the Sudanese culture taking much care of singles. Being a single in 
Sudan is not a risk factor for developing DR  TB. 
 
There was a trend toward an association between patients working in private sector 
and the development of DR. If that association should proved significant with a larger 
sample size, it may reflect the difficulties of accessibility to the health services related 
to the financial situation of the patients since those who are employee in private 
sector are more likely to afford access to the health services.  
 
We did not observe any association between the development of DR and the crowded 
living conditions. This may be due to the fact that people in Sudan sleep in big yards 
out side their rooms and the rooms are constructed with a wide space between the 
roof and the ground, windows and doors are usually kept open with a good ventilation 
inside the rooms. 
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Future perspectives 
 
The results of this study underline the necessity of eatablishing a National Reference 
Laboratory for TB in Sudan, in order to establish a national surveillance on anti-tTB 
DR in the whole country. Susceptibility testing for those who have interrupted their 
treatment or failed to be cured by ordinary anti-TB treatment is important in order to 
avoid errors in case management. Treatment of patients infected with DR M. 
tuberculosis must be prescribed according to the most likely susceptibility pattern 
established through national surveillance. For those infected with susceptible M. 
tuberculosis, treatment must be prescribed according to standard treatment regimens, 
which will eventually lead to cure of the patients.  
   
High prevalence of DR and MDR in previously treated patients might indicate poor 
patients’ and/or doctors’ compliance. Poor compliance causes accumulation of 
mutants resistant to ant-TB drugs. Spread and transmission of such strains will 
increase the problem of drug resistance in the community. This will cause serious 
problems for health services since second line treatment is expensive and have toxic 
effects. Drug sensitivity surveillance is thus a helpful tool for planning further ant-TB 
activities in Sudan.  
 
In Sudan all health workers in the NTP are well trained and educated for the 
management of TB.  
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Based on the analysis of these results NTP may already revise its policy on anti-TB 
treatment. For instances, high prevalence of drug resistance to S could initiate a 
discussion of whether to change the regimen by replacing S by E.  
 
Also patients who have interrupted their treatment are treated with the new patients’ 
treatment category (CAT 1). High prevalence of MDR and resistance to any drug 
among patients who have interrupted their medication could be avoided by treating 
them within the category for the previously treated patients (CAT2)  
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CONCLUSIONS AND RECOMMENDATIONS 
 
CONCULSIONS: 
  
1. There is a high prevalence of M. tuberculosis strains resistant to S also in new 
patients 
2. Drug resistance except for S among new cases is a rare phenomenon in Sudan, 
which indicates a low rate of transmission of resistant strains. 
3. Drug resistance among previously treated patients is present at an alarming level  
4. Resistance to two or three drugs is not a common phenomenon. 
5. Resistance to R predicts resistance to H and can serve as a valid marker of MDR 
6. Prevalence of MDR and drug resistance is associated with previous anti-TB 
treatment, being more than 40 years of age, long duration of disease symptoms 
(cough), low weight and household contact with a TB patient. 
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RECOMMENDATIONS: 
 
1. It is important to have a well functioning National Reference Laboratory in Sudan 
and reliable laboratory facilities to monitor/survey drug resistance in time. 
2. NTP should use all efforts to ensure proper cure of TB patients. 
3. S should be replaced by E in the first 2 months of the treatment. 
4. TAD patients should have been given CAT2 (3SRZE, 5RZE) initially. 
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DATA COLLECTION FORM 
 
 
 
Patient identity 
Card number:   
Date: D  M Y 
Name: _________________________________________ 
Sex:   M          F 
Age:    
Marital Status: Married      Unmarried       Divorced       Widowed 
Residence:      Urban         Rural 
Education: Illiterate        Literate 
Number of years completed: 
  Primary (1-6)                   Intermediate (7-9) 
 Secondary (10-12)            Post Secondary          Others 
Occupation: Government employee      Student             Labor 
Running small business     Running big business 
Unemployed                       Employee in private sector 
House Wife 
No of people per room:  
Address: __________________________________ 
 97
Tribe:   Northern              Southern         
Western               Eastern 
     Medical history 
Weight:  (…..) kg. 
Height:  (…..) cm. 
BCG  Scar: Present              Absent. 
HIV status: Positive             Negative 
Patient’ categorization: New case  Failure    Relapse   TAD 
Smoking: Present            Absent               Duration 
Main Complains Of Suspect: 
Cough: Present            Absent               Duration (………….) 
Weight loss Present            Absent               Duration (………….) 
Chest pain: Present            Absent               Duration (………….) 
Shortness of breath Present            Absent               Duration (………….) 
Fever:                   Present            Absent               Duration (………….) 
Night sweat:  Present            Absent               Duration (………….) 
Tiredness:  Present            Absent               Duration (………….) 
Hemptosis: Present            Absent               Duration (………….) 
Laboratory data: 
Smear microscopy: Positive          Negative 
Culture: Positive          Negative 
Result of susceptibility test (BACTEC): 
S  Susceptible              Resistance 
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H  Susceptible              Resistance 
R  Susceptible              Resistance 
E  Susceptible              Resistance 
Resistance to any drug  Susceptible              Resistance 
MDR:  Yes                           No 
 
 
 99
 
